On October 16, 2025, Cryo-Cell International, Inc. announced its fiscal third‑quarter 2025 results for the quarter ended August 31, 2025. The company reported consolidated revenue of $7.83 million, a 3% decline from $8.07 million in the same quarter of 2024. Net income for the quarter was $749,000, down from $1.05 million in the prior year.
Earnings per share for the quarter were $0.09 on a basic and diluted basis, compared with $0.13 in the same period of 2024. The company’s core cord blood banking and tissue services remain the primary revenue driver, while the slight revenue decline reflects a modest drop in new specimen processing volumes.
Cryo-Cell is the world’s first private cord blood bank, and it continues to leverage its proprietary PrepaCyte‑CB technology to maintain high stem‑cell recovery rates. The company’s public banking program, in partnership with Duke University, has supplied cord blood for more than 700 transplants and operates a donation site at Cedars‑Sinai Hospital in Los Angeles.
The Q3 2025 results demonstrate that Cryo-Cell remains profitable, though the revenue dip signals ongoing market pressure. The company’s continued positive earnings and its technological advantage position it to sustain its core business while navigating the competitive landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.